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ABSTRACT 25 
Background: Quantitative suspension arrays are powerful immunoassays to measure 26 
antibodies against multiple antigens in large numbers of samples in a short time and using 27 
few microliters. To identify antigen targets of immunity for vaccine development against 28 
complex microbes like malaria, such technology allows the characterization of the magnitude 29 
and antigenic specificity of Ig isotypes and subclasses that are important for functional 30 
responses. However, standardized assays are not widely available.  31 
Methods: We developed six quantitative suspension array assays for IgG1, IgG2, IgG3, 32 
IgG4, IgM and IgE specific to multiple P. falciparum antigens. Among commercially available 33 
sources, secondary and tertiary antibodies, as well as human purified antibodies for standard 34 
curves, were tested. Positive and negative controls included plasmas from malaria hyper-35 
immune African adults and from malaria-naïve European adults, respectively. Reagents were 36 
selected and optimal antibody and test sample dilutions established according to sensitivity, 37 
specificity and performance of the standard curves. The variability between replicates and 38 
plates was assessed with 30 test samples and controls.  39 
Results: Assays were able to detect P. falciparum antigen-specific antibodies for all isotypes 40 
and subclasses in samples from malaria-exposed individuals, with low background signal in 41 
blank wells. Levels detected in malaria-naïve individuals were overall low except for IgM. For 42 
the IgG2 and IgE assays, a triple sandwich was required for sensitivityStandard curves with 43 
5-parameter logistic fit were successfully obtained in all assays. The coefficients of variation 44 
for measurements performed in different days were all < 30%, and < 5% when comparing 45 
duplicates from the same plate. 46 
Conclusion: The isotype/subclass assays developed here were sensitive, specific, 47 
reproducible and of adequate quantification dynamic range. They allow performing detailed 48 
immuno-profiling to large panels of P. falciparum antigens to address naturally- and vaccine-49 
induced Ig responses and elucidate correlates of malaria protection, and could also be 50 
applied to other antigen panels.  51 
52 
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1. Introduction 53 
In the assessment of humoral immunity against complex infections such as Plasmodium 54 
parasites, still affecting 95 countries and with 3.2 billion people at risk in 20151, it is key to 55 
have immunoassays that can reliably measure multiple immunoglobulins (Ig) and antigens in 56 
a mid-high throughput miniaturized manner. Antigen and isotype/subclass targets of 57 
naturally-acquired immunity2, 3 need to be identified to characterize mechanisms of protection 58 
and find ways to induce them through vaccination.  59 
Most malaria sero-epidemiological and vaccine studies only measure antigen-specific IgG4, 5, 60 
since in the 60’s it was established that transfer of purified IgG can control P. falciparum 61 
infection6. Nevertheless, antigenic targets of protection are unknown, and diverse Ig isotypes 62 
and subclasses are generated in response to malaria infection7-10. These various isotypes 63 
could be differentially elicited by antigens and have different effector functions, some of them 64 
being protective while others not11-13. It is generally known that IgG1 and IgG3, both 65 
considered cytophilic antibodies, are the main subclasses generated against P. falciparum 66 
antigens14-16, but their relevance and function needs to be better studied. The most accepted 67 
mechanism by which IgG1 and IgG3 may protect against P. falciparum infection is through 68 
their ability to fix complement and mediate opsonizing phagocytosis17, 18. However, it needs 69 
to be better established whether non-cytophilic IgG2 and IgG4 antibodies, despite being 70 
present at low levels in exposed individuals, could be induced in detriment of cytophilic 71 
subclasses considered as protective, and to what extent their increase could be associated 72 
with risk of malaria. Furthermore, the role of IgM and IgE in malaria immunity has been less 73 
studied and merits more attention according to recent data associating those responses to 74 
protection19 or risk20-22, respectively. Therefore, an appropriate understanding of the 75 
magnitude and antigenic specificity of each of the Ig isotypes and subclasses is very 76 
important for the development of a new generation of effective vaccines. 77 
Traditionally, the measurement of specific antibodies has been done by the enzyme-linked 78 
immunosorbent assay (ELISA)23-25. Although this classical technique has been very useful 79 
over the years, it demands significant amount of time, the use of relatively large sample 80 
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volumes and, importantly, only allows quantifying antibodies against a single antigen at a 81 
time. A mid-high throughput multiplex alternative technique is the quantitative suspension 82 
array technology (qSAT), particularly suited for large parasites like P. falciparum that is 83 
estimated to contain around 5,000 proteins, many of which are polymorphic and/or variant, 84 
and stage-specific. qSAT has several advantages compared to ELISA already demonstrated 85 
in many studies in diverse research areas26-29. For example, qSAT allows working with 5 or 86 
less microliters of plasma, serum or saliva, and simultaneously quantify up to 500 different 87 
proteins/antibodies, peptides, RNA or DNA fragments in a single well. In addition the qSAT is 88 
a very flexible platform that allows different antibody sandwiches, representing a perfect tool 89 
to assess the levels of different Ig isotypes and subclasses in large numbers of samples.  90 
In this study, we have developed 6 different qSAT assays to measure antigen-specific IgG 91 
subclasses (1 to 4), IgM, and IgE using several panels of minimum 6 to 10 P. falciparum 92 
antigens. For this purpose, several antibody sandwiches were tested to choose the optimal 93 
combination for each isotype/subclass assay. In addition, isotype/subclass specific singleplex 94 
standard curves were developed to select sample dilutions for data analysis and to calibrate 95 
the assay. The variability of the assays between replicates and plates was also evaluated.  96 
 97 
2. Material and methods 98 
2.1. Human samples 99 
A plasma pool made of 22 samples from malaria hyper-immune adults from Manhiça, 100 
Mozambique30, was used as positive control. Fourteen individual plasma samples from 101 
European adults never exposed to malaria were used as negative controls. Test samples 102 
from 30 malaria-exposed individuals, adults and children, collected in the context of different 103 
immunological studies31-33, were assayed in the setting up and assessment of the different 104 
assays.  105 
Written informed consent was obtained from participants before sample collection; in the 106 
case of children the informed consent was obtained from parents or guardians. 107 
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Approval for the protocols was obtained from the Hospital Clínic of Barcelona Ethics Review 108 
Committee and the National Mozambican Ethics Review Committee.  109 
 110 
2.2. P. falciparum recombinant antigens  111 
A primary multiplex panel including 10 recombinant proteins with a broad range of 112 
immunogenicities was initially established to set up the IgG1-4 and IgM assays using the 113 
Luminex xMAPTM technology (Luminex Corp., Austin, Texas)32. The antigens were selected 114 
based on their important role as candidate vaccines, and for being representative of the 115 
different phases of the parasite life cycle. The panel included 4 pre-erythrocytic antigens: 116 
cell-traversal protein for ookinetes and sporozoites (CelTOS)34, liver-stage antigen 1 (LSA-117 
1)35, sporozoite surface protein 2 (SSP2, also known as TRAP)36 and circumsporozoite 118 
surface protein (CSP)37; and 6 erythrocytic antigens: apical membrane antigen 1 (AMA-1) 119 
from 3D7 and FVO strains38-40, merozoite surface protein 1 (MSP-142) from 3D7 and FVO 120 
strains41, 42, fragment II of region II of the 175 kDa erythrocyte binding protein (EBA-175 or 121 
PfF2)43, and Duffy binding-like alpha (DBL-α) domain of PfEMP-144. P. falciparum AMA- and 122 
MSP-1 are polymorphic proteins, and the two most studied strains are 3D7 and FVO. 123 
Antigens based on primary sequences from both strains have been developed as vaccine 124 
candidates because of the strain-specific nature of antibody responses to many malarial 125 
antigens. Experimental vaccines based on only one genotype of these proteins have been 126 
tested in field trials showing different degree of protection depending on the circulating 127 
strain45, 46. As antibody responses to polymorphic proteins may vary in different populations, 128 
we included AMA-1 and MSP-1 from both strains in the panel to have a broader repertoire 129 
and check whether they elicited different IgM and IgG subclass responses. A bovine serine 130 
albumin (BSA)-coupled bead was also included in the multiplex for background 131 
determination. The pre-erythrocytic antigens were expressed in Pichia Pastoris and provided 132 
by Protein Potential, LLC (Rockville, Maryland, USA). AMA-1 3D7, EBA-175 and DBLα were 133 
provided by the International Centre for Genetic Engineering and Biotechnology (ICGEB). 134 
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AMA-1 FVO and MSP-142 3D7 and FVO were provided by the Walter Reed Army Institute of 135 
Research (WRAIR). The BSA was purchased to Sigma-Aldrich.  136 
A secondary panel was used to set up an antigen-specific IgE assay, including those 137 
antigens showing some IgE reactivity in previous tests using a positive pool (data not 138 
shown). The antigens included in the IgE panel were: the Exported Protein 1 (EXP-1, Protein 139 
Potential), Merozoite Surface Protein 3 (MSP-3 3D7, ICGEB), Merozoite Surface Protein 2 140 
3D7 strain type CH150 (MSP-2 3D7 CH150, Edinburgh University), CSP full length (Protein 141 
Potential), NANP repeat region (NANP, WRAIR) and C-term region (C-term, WRAIR).  142 
 143 
2.3. Coupling of recombinant antigens to microspheres  144 
MAGPLEX 6.5µm COOH-microspheres were purchased from Luminex Corporation (Austin, 145 
TX). The bead stock was gently resuspended on a rotary shaker for 30 min, followed by soft 146 
vortexing for 1 min and sonicated for 30 sec. The amount of beads to be coupled to each 147 
antigen was calculated assuming the use of 1,000 beads per region and per sample, and a 148 
maximum of 2.5 106 beads in 250µl reaction volume. The beads were washed twice with 149 
250µl of distilled water in a concentration of 10,000 beads/µL by short vortex and sonication 150 
for 20 sec, and using a magnetic separator (Life Technologies, ref. 12321d). Next, the beads 151 
were resuspended in 80µl of activation buffer, 100mM monobasic sodium phosphate (Sigma, 152 
S2554), pH 6.2 by vortex and sonication for 20 sec. To activate the beads for cross-linking to 153 
proteins, 10µl of 50mg/ml Sulfo-N-hydroxysulfosuccinimide (Thermo Fisher Scientific, ref. 154 
24525) and 10µl of 50mg/ml 1-Ethyl-3-[3-dimethylaminopropyl]-carbodiimidehydrochloride 155 
(Thermo Fisher Scientific, ref. 22981) were simultaneously added to the reaction tubes, 156 
mixed gently by vortexing and incubated for 20 min, at room temperature (RT), in a rotary 157 
shaker and protected from light. Microspheres were washed twice with 250µl 50mM 158 
morpholineethane sulfonic acid (MES) (Sigma ref. M1317) pH 5.0, or with phosphate 159 
buffered saline (Sigma ref. BE17-512F) pH 7.4 (Table 1), in a 10,000 beads/µL concentration 160 
by vortex and sonication for approximately 20 sec.  161 
7 
 
 162 
Table 1 163 
Panel of Plasmodium falciparum and control antigens with their corresponding coupling 164 
concentration and the optimal coupling buffer.  165 
 166 
Antigen 
Coupling 
concentration 
Buffer 
AMA-1 3D7 20 μg/mL MES 
AMA-1 FVO 20 μg/mL MES 
MSP-142 3D7 20 μg/mL MES 
MSP-142 FVO 20 μg/mL MES 
EBA-175 20 μg/mL PBS 
CelTOS 50 μg/mL PBS 
LSA-1 20 μg/mL PBS 
SSP2 10 μg/mL PBS 
DBL-α 30 μg/mL PBS 
CSP 10 μg/mL MES 
MSP-3 3D7 30 μg/mL MES 
MSP-2 3D7 CH150 30 μg/mL MES 
CSP C-term 30 μg/mL MES 
CSP NANP 30 μg/mL MES 
EXP-1 30 μg/mL MES 
BSA PBS-BSA1% PBS 
 167 
Beads were first conjugated to the different antigens in a range of concentrations between 168 
10-50 μg/mL to choose the optimal one for couplings. Then, the appropriate amount of each 169 
antigen per million beads (Table 1) was added to each reaction tube in 500µl MES or PBS 170 
(10,000 beads/uL), and they were left on a rotary shaker overnight at 4ºC, protected from 171 
light. Next day, beads were brought to RT in agitation for 20 min, and were blocked with 172 
500µl PBS-BN (PBS with 1% BSA (Santa Cruz, SC-2323A) and 0.05% sodium azide (Sigma 173 
ref. S8032)) in agitation during 30 min at RT and protected from light. Beads were washed 174 
twice with PBS-BN by short vortex and sonication for 20 sec and using the magnetic 175 
separator. To determine the percentage recovery after the coupling procedure, coupled 176 
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beads were resuspended in 500µl PBS-BN and counted on a Guava PCA desktop cytometer 177 
(Guava Technologies, Automated cell counter, PC550IG-C4C / 0746-2747).  178 
Antigen-coupled beads were validated in singleplex and multiplexed by measuring total IgG 179 
in serial dilutions of the positive control. Coupled beads were stored multiplexed at 1,000 180 
beads/µl/region at 4ºC and protected from light.  181 
 182 
2.4. Coupling of anti-IgM, anti-IgG and anti-IgE antibodies to microspheres for the standard 183 
curves 184 
Anti-human IgM (KPL, ref.201-1003), anti-human Fab-IgG (Jackson Immunoresearch, ref. 185 
109-006-097) and anti-human IgE (Abcam, ref. ab99834) antibodies were separately coupled 186 
to microspheres at 50 μg/mL following the coupling procedure above indicated. Antibody-187 
coupled beads were tested in singleplex with serial dilutions of the corresponding human 188 
purified immunoglobulin: IgM (Sigma-Aldrich, ref. I8260), IgG1 (Abcam, ref. ab90283), IgG2 189 
(Abcam, ref. ab90284), IgG3 (Abcam, ref. ab138703), IgG4 (Abcam, ref. ab90286) and IgE 190 
(Abcam, ref. ab65866). Antibody-coupled beads for the standard curves were stored at 2,000 191 
beads/µl at 4ºC and protected from light. Anti-human IgE coupled beads were also used to 192 
measure total IgE in the test samples. 193 
 194 
2.5. General assay procedures 195 
Several biotinilated secondary antibodies were tested against the positive and negative 196 
controls to assess their ability to detect IgM, IgG1, IgG2, IgG3, IgG4, and IgE in plasma 197 
samples. In parallel, for each specific assay we evaluated the best combination of primary 198 
and secondary antibody pairs to create a standard curve of serial dilutions of the 199 
corresponding human purified isotype/subclass (Fig. 1). Standard curves of antibody 200 
concentrations versus MFIs were fitted using a 5-parameter (5PL) or a 4-parameter (4PL) 201 
logistic equation depending on the best yield (superior fit to antibody data). If 5-PL regression 202 
model did not converge, then a 4-PL method without asymmetry factor was fitted instead, 203 
following the formula MFI=Emax+((Emin-Emax)/((1+((Conc/EC50)^Hill))^Asym)), where EC50 204 
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is the half maximal effective concentration, Emin is the minimum response, Emax is the 205 
maximum response, Asym is the asymmetry factor and Hill is the slope factor. Titration of 206 
antibodies and optimal sample dilutions were assessed through several tests.  207 
 208 
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Fig. 1. Examples of IgG1, IgG2, IgG3, IgG4, IgM and IgE standard curves prepared with 212 
serial dilutions of the corresponding human purified isotype/subclass. 213 
 214 
Regarding the general assay procedures, we followed the previously described total IgG 215 
protocol with some modifications32, 47. First, antigen-coupled microspheres were added to a 216 
96-well μClear® flat bottom plate (Greiner Bio-One, ref. 655096) in multiplex (1,000 217 
microspheres per analyte per well)48 in a volume of 50µL of PBS-BN and incubated with 218 
50µL of serial dilutions of the positive control (usually between the range 1/10-1/400,000) 219 
and the negative controls (at the first dilution of the positive control). A couple of wells per 220 
plate were designated to blanks where beads were incubated with PBS-BN to measure 221 
background signal. As standard curve, anti-IgM, anti-IgG or anti-IgE coupled microspheres 222 
were added in singleplex (2,000 microspheres per well) in a volume of 50µL of PBS-BN and 223 
incubated with 50µl of 2-fold serial dilutions of the corresponding purified human IgM, IgG1, 224 
IgG2, IgG3, IgG4 or IgE. Next, plates were incubated during 1h at 600 rpm in a microplate 225 
shaker (Corning, LSE Digital Microplate Shaker ref. CLS67814-1EA) at RT and protected 226 
from light. After the incubation, plates were washed manually three times with 200µl/well of 227 
wash buffer (PBS-Tween20 0.05%) on a magnetic washer (Millipore, ref. 40-285). A hundred 228 
microliters of biotinilated secondary antibody (anti-human IgM, IgG1, IgG2, IgG3, IgG4 or 229 
IgE) diluted in PBS-BN were added to all wells and incubated 45 min at 600rpm, RT and 230 
protected from light. The plate was washed as before and 100µl of streptavidin-R-231 
phycoerythrin (Sigma, ref. 42250) diluted 1:1,000 in PBS-BN were added to all wells and 232 
incubated 30 min at 600rpm, RT and protected from light. Plates were washed three times as 233 
before, and beads resuspended in 100µl of PBS-BN and immediately read using the 234 
Luminex xMAP® 100/200 analyzer. At least 50 beads per analyte were acquired per sample. 235 
Crude median fluorescent intensity (MFI) and background fluorescence from blank wells 236 
were exported.  237 
 238 
2.6. Use of a tertiary antibody in the antigen-specific IgG2 and IgE assays  239 
11 
 
The double antibody sandwiches tested for the antigen-specific IgG2 and IgE assays did not 240 
render enough signal for the measurement of these two antibodies. To increase the 241 
sensitivity of the assays we added a tertiary antibody. For these triple sandwiches, the 242 
secondary antibodies used were unconjugated mouse anti-human IgG2 and anti-human IgE 243 
diluted 1/500 in PBS-BN. The secondary antibody was incubated 60 min, followed by an 244 
incubation with anti-mouse IgG-Biotin diluted 1/1,000 in PBS-BN for 60 min, and a last 245 
incubation with streptavidin-R-phycoerythrin diluted 1:1,000 in PBS-BN 30 min. Incubations 246 
and washes in-between were as indicated in the previous section. 247 
 248 
2.7. Assay reproducibility 249 
For each isotype and IgG subclass, the coefficient of variation (CV%) was assessed for the 250 
duplicates and for the repeated measurements of the positive control in different plates. 251 
Means of CV% of duplicates per antigen and isotype-subclass were calculated. 252 
 253 
3. Results  254 
In the optimization of the IgGs and IgE assays, many different reagents and antibody 255 
sandwiches were tested, some of them discarded because there was no recognition of their 256 
expected target, or due to unspecific binding to other IgG subclasses or even to the antigen-257 
coupled beads. Here we present the antibody combinations that better detected antigen-258 
specific antibodies in human plasma or serum samples and that better worked for the 259 
development of the corresponding standard curves.  260 
 261 
3.1. Standard curves 262 
The primary human purified Ig used for the development of the standard curves are shown in 263 
Table 2, where serial dilutions are detailed. Figure 1 shows examples of the performance of 264 
each standard curve.   265 
 266 
Table 2 267 
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Details of primary antibody dilutions used for the development of the standard curves.  268 
Human purified Ig 
isotype/subclass 
Fold 
dilution 
Starting 
concentration 
(ng/ml) 
Final 
concentration 
(ng/ml) 
Serial 
dilutions 
IgM (Sigma-Aldrich, I8260) 2 1250 0.009536743 18 
IgG1 (Abcam, ab90283) 2 1000 0.00762939 18 
IgG2 (Abcam, ab90284) 2 2000 0.06103516 16 
IgG3 (Abcam, ab138703) 2 1000 0.00762939 18 
IgG4 (Abcam, ab90286) 2 500 0.01525879 16 
IgE (Abcam, ab65866) 2 2000 0.06103516 16 
 269 
3.2. Optimal antibody sandwiches and dilutions for each Ig isotype/subclass assay 270 
The primary antibodies used for the optimization of the assays were the same used for the 271 
standard curves (Table 2). For the selection of the secondary and tertiary antibodies, the 272 
main criterion used was the generation of good standard curves. Antibodies selected were 273 
titrated to find optimal assay dilutions (Table 3).  274 
 275 
Table 3 276 
Details of secondary-tertiary antibodies and Streptavidin-Phycoerythrin (SA-PE) reagents. 277 
Ig Secondary antibody Tertiary antibody SA-PE 
IgG1 
anti-IgG1-Biotin 
(Abcam, ab99775) 
1:4000 
- 
Streptavidin-R-
phycoerythrin 
(Sigma, 42250) 
1:1000 
IgG2 
mouse anti-human IgG2 
(Thermo Fisher, MA1-
34755) 1:500 
goat anti-mouse IgG-
Biotin (Sigma, 
B7401-1ML) 1:1000 
IgG3 
anti-IgG3-Biotin (Sigma, 
B3523) 1:1000 
- 
IgG4 
anti- IgG4-Biotin 
(Sigma, B3648) 1:8000 
- 
IgM 
anti-IgM-Biotin (Sigma, 
B1265) 1:1000 
- 
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Antigen-specific IgE 
Mouse anti-human IgE 
(Abcam, ab99834) 
1:250 
goat anti-mouse IgG-
Biotin (Sigma, 
B7401-1ML) 1:125 
Total IgE 
anti-IgE-Biotin (Thermo 
Fisher, A18803) 1:2000 
- 
 278 
The human purified IgM captured by anti-IgM-coupled beads was detected by anti-IgM-Biotin 279 
(Sigma, B1265) diluted 1:1000. The human purified IgG1, 3 and 4 subclasses separately 280 
captured by anti-IgG-coupled beads were detected by anti-human IgG1-Biotin (Abcam, 281 
ab99775) at dilution 1:4,000, anti-human IgG3-Biotin (Sigma, B3523) at dilution 1:1,000 and 282 
anti-human IgG4-Biotin (Sigma, B3648) at dilution 1:8,000, respectively. For the IgG2 assay, 283 
after testing many different reagents, suppliers and incubation times, we did not find any 284 
biotinilated secondary antibody that performed properly. We solved the problem by using a 285 
triple sandwich including a secondary plus a tertiary biotinilated antibody: an unconjugated 286 
mouse anti-human IgG2 (Thermo Fisher, MA1-34755) diluted 1:500 and a goat anti-mouse 287 
IgG-Biotin (Sigma, B7401-1ML) diluted 1:1,000. The same situation happened for the 288 
antigen-specific IgE assay, therefore we chose as secondary antibody an unconjugated 289 
mouse anti-human IgE (Abcam, ab99834) diluted 1:250 and a goat anti-mouse IgG-Biotin 290 
(Sigma, B7401-1ML) diluted 1:125 as tertiary antibody. Separately, for an assay measuring 291 
total IgE, the primary antibody was captured by anti-IgE coupled beads and detected by anti-292 
human IgE-Biotin (Thermo Fisher, A18803) diluted 1:2000. For all of the assays, the 293 
streptavidin-PE incubation was optimal at a 1:1000 dilution. Once all assays were developed, 294 
we decided to also test a triple sandwich for IgG4 to make it more comparable to IgG2, the 295 
other minority non-cytophilic subclass. The IgG4 triple sandwich was successfully developed, 296 
and antibodies and dilutions finally selected were: a mouse anti-human IgG4 (Thermo Fisher, 297 
MA1-80332) diluted 1:8,000 and the goat anti-mouse IgG-Biotin (Sigma, B7401-1ML) diluted 298 
1:1,000.  299 
 300 
3.3. Optimal plasma dilutions for each isotype/subclass assay 301 
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To determine the optimal sample dilutions, plasmas from 30 Mozambican individuals were 302 
tested in serial dilutions chosen depending on the expected levels for each Ig against P. 303 
falciparum antigens. Samples were diluted from 1:200 to 1:204,800 for IgM (Fig. 2), 1:400 to 304 
1:1,638,400 for IgG1, 1:200 to 1:437,400 for IgG3 (Fig. 3), 1:50 to 1:12,800 for IgG2 and 305 
IgG4 (Fig. 4), and 1:10 to 1:1,771,470 for antigen-specific IgE and 1:50 to 1:25,600 for the 306 
total IgE assays (Fig. 5). To test the triple sandwich IgG4 assay, serial dilutions (1:100 to 307 
1:13,107,200) of a pool of plasmas from hyperimmune adults were tested (Fig. 4). 308 
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Fig. 2. Example of IgM levels measured in serial dilutions of plasma samples from 3 311 
Mozambican adults against a panel of 8 Plasmodium falciparum antigens using anti-IgM-312 
Biotin diluted 1:1,000 and streptavidin-PE at 1:1,000.  313 
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Fig. 3. Examples of IgG1 (subjects 4,5 and 6) and IgG3 (subjects 7, 8 and 9) levels 326 
measured in serial dilutions of plasma samples from 6 Mozambican adults against a panel of 327 
10 Plasmodium falciparum antigens using anti-human IgG1-Biotin at 1:4,000 and anti-human 328 
IgG3-Biotin at 1:1,000, respectively, and streptavidin-PE at 1:1,000.  329 
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IgG4 (triple sandwich)  336 
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Fig. 4. Examples of IgG2 (subjects 10, 11 and 12) and IgG4 (subjects 13, 14 and 15) levels 338 
measured in serial dilutions of plasma samples from 6 Mozambican adults against a panel of 339 
10 Plasmodium falciparum antigens using a triple (mouse anti-human IgG2 at 1:500 plus 340 
goat anti-mouse IgG-Biotin at 1:1,000) and double sandwich (anti-human IgG4-Biotin at 341 
1:8,000), respectively, and incubated with streptavidin-PE at 1:1,000. Data obtained using a 342 
triple sandwich (mouse anti-human at 1:8,000 plus goat anti-mouse IgG-Biotin at 1:1,000) to 343 
measure IgG4 in a pool of plasmas from hyperimmune adults are also shown.  344 
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Fig. 5. Total (subjects 16, 17 and 18) and antigen-specific (subjects 19, 20 and 21) IgE levels 358 
measured in serial dilutions of plasma samples from 6 Mozambican children. Total IgE has 359 
been measured using an anti-human IgE-Biotin diluted 1:2,000. IgE antigen-specific levels 360 
have been measured against a panel of 6 Plasmodium falciparum antigens using an 361 
unconjugated mouse anti-human IgE diluted 1:250 and a goat anti-mouse IgG-Biotin diluted 362 
1:125. Streptavidin-PE was incubated at a 1:1,000. 363 
 364 
IgM, IgG1 and IgG3 individual responses to the different antigens were of very different 365 
magnitudes (Fig. 2 and 3). IgG2, IgG4 and IgE responses in almost all the tested individuals 366 
were overall weak (Fig. 4 and 5). Accordingly to these results, for IgM, IgG1 and IgG3 we 367 
concluded to work with at least two dilutions per sample to increase the chances of one 368 
falling in the linear part of the standard curve, assuring reliable measurements. On the other 369 
hand, for IgG2, IgG4 and total IgE, we concluded that only one plasma dilution was needed 370 
because of the low signals observed. For the antigen-specific IgE assay, we decided to use 4 371 
serial dilutions, being an almost unexplored isotype in the malaria field. Therefore, we chose 372 
1:200 and 1:20,000 sample dilutions for IgM assay; 1:400 and 1:12,000 for IgG1; 1:200 and 373 
1:1,000 for IgG3; 1:50 for IgG2, IgG4 and total IgE; and 1:30, 1:270, 1:2,430 and 1:21,870 for 374 
specific IgE. 375 
The positive control was assayed in the same dilutions as the samples. For the negative 376 
controls (European naïve individuals) the dilution chosen was the samples’ most 377 
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concentrated for each isotype/subclass. Figure 6 shows examples of antibody levels in 378 
plasma samples from negative controls. Some malaria naïve individuals had a signal against 379 
some P. falciparum antigens, probably because of cross-reactivity of non-specific antibodies. 380 
For IgM, unspecific responses of negative controls were higher than for the other antibodies.  381 
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 387 
Fig. 6. Example of levels of antigen-specific IgG1, IgG2, IgG3, IgG4, IgM and IgE measured 388 
in plasma from European naïve individuals, at the dilutions 1:400, 1:50, 1:200, 1:50, 1:200 389 
and 1:30, respectively. 390 
 391 
All 6 antigen-specific Ig assays showed very low background signals measured in blank wells 392 
(Fig. 7), being the antigen-specific IgE assay the one with higher MFIs when no sample was 393 
incubated.  394 
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Fig. 7. Levels of background signal in each antigen-specific isotype/subclass assay.  400 
 401 
3.4. Reproducibility intra- and inter-plate 402 
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Data from the positive controls (two dilutions for IgM, IgG1 and IgG3, one dilution for IgG2 403 
and IgG4, and 4 dilutions for IgE) were tested in duplicates during 2 consecutive days in 7 404 
different plates to assess the reproducibility of the assay between duplicates and plates. CVs 405 
between duplicates were 3.32% (1.13-5.09) for IgM, 3.27% (0.32-6.08) for IgG1, 3.98% (1.6-406 
7.61) for IgG2, 3.72% (0.41-6.65) for IgG3, 3.66% (1.03-5.73) for IgG4, 4.45% (3.14-5.44) for 407 
specific IgE and 2.86% (2.26-3.47) for total IgE. The overall CV was 3.47%, indicating that 408 
the measurements were consistent. The CVs between different plates are shown in Table 4 409 
(IgG1, IgG2, IgG3, IgG4 and IgM) and Table 5 (IgE) with CVs ranging from 1.55% to 27.58%. 410 
 411 
Table 4 412 
Coefficients of variability of repeated measurements of Plasmodium antigen-specific IgG1, 413 
IgG2, IgG3, IgG4 and IgM assayed in the positive control. 414 
 415 
Ig Dilution 
AMA-1 
3D7 
AMA-1 
FVO 
MSP-
142 3D7 
MSP-
142 FVO 
EBA-
175 
CelTOS LSA-1 SSP2 DBL-α CSP 
IgG1 
1 1.75 1.55 5.16 2.3 20.02 6.58 11.76 6.34 10.12 12.64 
2 5.01 7.22 9.75 15.01 4.49 3.33 3.2 3.13 3.68 3 
IgG2 1 8.93 7.33 9.65 13.33 4.9 8.24 12.6 8.56 9.67 9.31 
IgG3 
1 1.59 1.7 11.53 3.14 7.65 12.45 19.68 27.4 15.12 26.41 
2 14.54 11.03 20.33 18.68 21.09 5.42 7.64 19.55 4.69 18.75 
IgG4 1 4.68 7.08 4.02 2.96 6.21 2.8 5.21 5.05 5.75 2.42 
IgM 
1 21.78 19.86 18.27 7.69 18.75 16.32 13.14 18.95 16.9 13.22 
2 20.62 22.63 19.44 27.58 24.71 19.5 16.42 21.23 24.36 21.57 
 416 
Table 5 417 
Coefficients of variation. 5A. Repeated measurements of antigen-specific IgE assayed with 418 
the positive control pool. 5B. Repeated measurements of total IgE. 419 
A. 420 
Ig Dilution 
MSP-3 
3D7 
MSP-2 
3D7 
CH150 
C-term NANP CSP EXP-1 
Antigen- 1 16.4 13.51 14.43 16.15 17.38 16.27 
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specific 
IgE 
2 11.06 5.99 9.79 8.52 7.35 10.45 
3 11.92 17.03 9.89 8.06 6.97 18.38 
4 9.55 13.71 17.15 14.16 13.28 18.47 
 421 
B. 422 
Ig CV% 
Total 
IgE 
5.24 
 423 
 424 
 425 
4. Discussion 426 
The identification of the antibodies generated after infection or vaccination, their magnitude, 427 
and their antigen specificity, are essential to improve the development of more efficient 428 
vaccines against malaria. With this purpose, we have developed six qSAT protocols to 429 
measure antigen-specific IgM, IgG1, IgG2, IgG3, IgG4 and IgGE against P. falciparum 430 
antigens. 431 
Many studies in the field of human humoral response to P. falciparum have been conducted 432 
using the ELISA24, 33, 49, 50 or qSAT48 5, 51. However, to our knowledge, this is the first time that 433 
the qSAT has been adapted to measure different antigen-specific Ig isotypes and 434 
subclasses, specifically IgM, IgG1, IgG2, IgG3, IgG4 and IgE using a multiplex panel of P. 435 
falciparum pre-erythrocytic and blood stage antigens.  436 
The most difficult part during the development of the assays was finding the right 437 
combination of antibody pairs able to detect both the human purified Ig used in the standard 438 
curves and the natural Ig present in plasma samples. There are many commercial sources 439 
with a large catalogue of biotinylated secondary antibodies available and it is difficult to know 440 
where to start. Even with reagents referenced in published studies, we did not always get 441 
acceptable results. For some antibody combinations, we did not get any signal. For others, 442 
we got signals in the standard curves but not in the samples, or vice versa; others showed 443 
26 
 
high background signals. Another challenge we faced was that some secondary antibodies 444 
had very variable bath-to-batch activity, forcing us to titrate each new lot and always test for 445 
background signal. In the case of IgG2 and IgE assays, where we finally decided to use of a 446 
triple sandwich, a double titration was required including secondary and tertiary antibodies. 447 
All these requirements made the optimization of these assays a labor-intense and long 448 
process.  449 
The use of a triple sandwich for IgG2 and IgE was chosen to increase the sensibility of the 450 
assays because the double sandwich yielded very poor signals. In addition, despite having 451 
developed a successful IgG4 assay using a double sandwich, the use of a triple sandwich 452 
also increased the sensibility, thus being adopted for subsequent studies.   453 
Regarding assay reproducibility, the CVs between plates never reached 30% for any 454 
isotype/subclass, however it was between 20-30% for some antigens. To decrease the 455 
variability and increase the accuracy of the assays, future optimization efforts will explore 456 
modifying samples incubation times and temperatures. 457 
Concerning assay specificity, the anti-P. falciparum-Ig signal detected in negative controls 458 
was overall low except in few subjects for IgG2, and especially for IgM, reaching high MFIs in 459 
some individuals. IgM has as a natural quality to be highly polyreactive against foreign and 460 
self-antigens, and it is thought to aid in the neutralization of pathogens prior to the 461 
development of high affinity, antigen-specific antibodies; it may also facilitate the clearance of 462 
apoptotic cells and/or autoantigen-immunocomplexes52. The possibility that this polyreactivity 463 
could provide some protection against pathogens that have not yet ben “seen” by the 464 
immune system of the host has been proposed53, 54. Thus, even in the naïve population (as 465 
are our negative controls) unexpected elevated levels of IgM with these characteristics can 466 
be detected. A cross-reactivity of IgM with antigens from other pathogens to which the 467 
negative controls have been exposed is another plausible explanation. Nevertheless, other 468 
negative controls will be tested in future IgM assays to find out if this was a problem with 469 
these specific negative controls or if it is something generalized. In parallel, other reagents, 470 
such as the biotinylated detection antibody, and other assay conditions like the temperature 471 
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of samples incubation, will be assessed to try to reduce the background signal and improve 472 
the assay performance. Nevertheless, the rest of assay background signals were low, 473 
between 61 and 276 MFI overall. All secondary and tertiary antibodies were selected 474 
because they showed levels below 300 MFI. Some reagents were discarded for having 475 
higher than expected background. The IgE-specific assay was the one with higher values but 476 
still considered in a good range. 477 
The inclusion of a standard curve55 in the assay is important as a quality control tool and 478 
applicable to choose the adequate sample dilution closer to EC50, to be used in data 479 
preprocessing. The standard curve may also be used for the normalization of the data to 480 
correct the variability between plates. This can be done by using a dilution point in the linear 481 
part of the curve to calculate a correction factor as the ratio between the median of this point 482 
from all plates divided by the same point in the specific plate. The normalization factor is then 483 
isotype-specific. In addition, the standard curve can also be used to calculate concentrations 484 
in arbitrary units, as was done for IgG and IgM assays in prior studies32, 47.  485 
Regarding the selection of the sample dilutions optimal for each isotype/subclass assay, the 486 
choice will always depend on several factors: i) the demographic and clinical characteristics 487 
of the study population, (i.e. age, level of malaria exposure, pregnancy, treatment), ii) the 488 
objective of the study (i.e. to explore natural or artificially-acquired immunity through 489 
vaccination), and iii) the immunogenicity of the antigens in the study panel. In the case of P. 490 
falciparum immunoassays, and to assure that at least one sample dilution will always fall on 491 
the linear (quantifiable) part of the standard curve, we recommend to test them in at least two 492 
dilutions for IgM, IgG1 and IgG3, while only one dilution may be required for IgG2 and IgG4. 493 
Regarding total and antigen-specific IgE assays, we suggest 1 dilution for total IgE and 4 494 
dilutions for antigen-specific IgE, since little is known about this isotype in malaria immunity. 495 
Nevertheless, we reiterate that depending on the characteristics of the study population and 496 
the immunogenicity of the antigens included in the panel, several serial dilution(s) of a 497 
representative set of samples have to be previously tested to guarantee an optimal choice 498 
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and avoid out-of-range MFI values in the qSAT, or other difficulties like the prozone or hook 499 
effect56. 500 
Beyond malaria, a great advantage of the qSAT is the possibility to optimize the 501 
measurement of different antibody isotypes and subclasses against all kinds of antigens from 502 
all kind of pathogens or conditions. This is a very powerful tool to address co-infections, a 503 
common situation in malaria endemic countries but often ignored when immune responses 504 
are explored and addressed individually. 505 
 506 
5. Conclusion 507 
A better characterization of the human immune response against P. falciparum is key to 508 
understand the mechanisms underlying protection, which in turn will allow the design of more 509 
effective vaccines. The 6 assays developed in this study demonstrate that the qSAT is a 510 
powerful mid-high throughput approach to evaluate antigen-specific responses of different Ig 511 
isotype/subclasses against multiplexed P. falciparum antigens. These 6 assays will allow 512 
performing detailed immuno-profilings against antigens from P. falciparum and other 513 
pathogens to better address natural and vaccine-induced humoral immune responses.  514 
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